1 week Ago By ABMN Staff
NRI Wealth Management LC purchased a new stake in shares of Cryoport, Inc. ( NASDAQ:CYRX – Free Report ) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 19,131 shares of the company’s stock, valued at approximately $149,000.
Cryoport comprises 0.1% of NRI Wealth Management LC’s portfolio, making the stock its 25th largest position. Several other large investors have also recently made changes to their positions in the business.
Quest Partners LLC grew its holdings in shares of Cryoport by 1,083,000.0% during the 2nd quarter. Quest Partners LLC now owns 10,831 shares of the company’s stock valued at $75,000 after purchasing an additional 10,830 shares during the last quarter.
Dynamic Technology Lab Private Ltd purchased a new stake in Cryoport during the third quarter valued at about $82,000. Hsbc Holdings PLC purchased a new stake in Cryoport during the second quarter valued at about $92,000. Intech Investment Management LLC bought a new position in shares of Cryoport during the third quarter valued at about $105,000.
Finally, The Manufacturers Life Insurance Company increased its holdings in shares of Cryoport by 9.5% in the second quarter. The Manufacturers Life Insurance Company now owns 17,683 shares of the company’s stock worth $122,000 after buying an additional 1,534 shares during the period.
92.90% of the stock is owned by hedge funds and other institutional investors. Wall Street Analyst Weigh In Several brokerages recently weighed in on CYRX.
Guggenheim started coverage on Cryoport in a report on Thursday, December 19th. They set a “buy” rating and a $11.00 target price for the company.
UBS Group boosted their price objective on Cryoport from $7.00 to $9.00 and gave the company a “neutral” rating in a research report on Friday, October 18th.
Finally, Roth Mkm cut their target price on shares of Cryoport from $18.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, November 8th.
Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, Cryoport has an average rating of “Moderate Buy” and an average price target of $12.29.
Insider Buying and Selling In related news, CEO Jerrell Shelton sold 50,000 shares of the stock in a transaction dated Thursday, November 21st. The shares were sold at an average price of $6.51, for a total value of $325,500.
00. Following the completion of the transaction, the chief executive officer now directly owns 731,897 shares of the company’s stock, valued at $4,764,649.47.
This represents a 6.39 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link .
Also, Director Ramkumar Mandalam sold 7,369 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $7.46, for a total transaction of $54,972.
74. Following the completion of the sale, the director now owns 59,497 shares of the company’s stock, valued at $443,847.62.
This trade represents a 11.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here .
Insiders sold 109,869 shares of company stock valued at $735,673 over the last quarter. 10.10% of the stock is owned by company insiders.
Cryoport Price Performance Shares of CYRX stock opened at $7.98 on Friday. The company has a debt-to-equity ratio of 0.
48, a quick ratio of 5.32 and a current ratio of 5.70.
Cryoport, Inc. has a fifty-two week low of $5.32 and a fifty-two week high of $20.
10. The firm has a market cap of $394.46 million, a P/E ratio of -2.
36 and a beta of 1.62. The business’s 50 day moving average price is $7.
51 and its 200-day moving average price is $7.85. Cryoport Company Profile ( Free Report ) Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. Read More Want to see what other hedge funds are holding CYRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cryoport, Inc.
( NASDAQ:CYRX – Free Report ). Receive News & Ratings for Cryoport Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryoport and related companies with MarketBeat.com's FREE daily email newsletter .
.
